Express News | Merck Shares Are Trading Higher After the Company and Orion Announced the Mutual Exercise of an Option to Convert the Companies' Ongoing Co-development and Co-commercialization Agreement for Opevesostat Into an Exclusive Global License for Merck

Benzinga12:34 ET

Deutsche Numis Downgrades Merck & Co(MRK.US) to Hold Rating, Raises Target Price to $140

Deutsche Numis analyst James Shin downgrades $Merck & Co(MRK.US)$ to a hold rating, and adjusts the target price from $135 to $140.According to TipRanks data, the analyst has a success rate of 61.5% a

Moomoo NewsJun 28 09:33 ET · Ratings

Market Whales and Their Recent Bets on MRK Options

Investors with a lot of money to spend have taken a bearish stance on Merck & Co (NYSE:MRK).And retail traders should know.We noticed this today when the positions showed up on publicly available opti

BenzingaJul 1 11:47 ET

Express News | Merck Shares up 3.8%

ReutersJul 1 09:56 ET

Orion Upgrades FY24 Outlook After Modifying Agreement With Merck & Co

Orion (ORNAV.HE, ORNBV.HE) upwardly revised its full-year outlook after its development and commercialization deal with US-based Merck & Co was converted into a global license for the latter, accordin

MT NewswiresJul 1 09:23 ET

Merck, Orion Convert Collaboration Into Exclusive License

By Colin Kellaher Merck & Co. and Finland's Orion have agreed to convert a 2022 co-development and co-commercialization agreement into an exclusive global license for Merck. The companies on Monday

WSJJul 1 08:50 ET